Metabolic Flexibility Support.

Long-chain fatty acids cannot cross the inner mitochondrial membrane as acyl-CoA; carnitine palmitoyltransferase I transfers them to carnitine first. Without adequate carnitine the fat-oxidation arm of substrate switching is capacity-limited. This is textbook transport biochemistry, not a claim that supplemental carnitine raises fat oxidation in people with normal status.

Lipoic acid is the covalently bound cofactor of the pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes. Those complexes are the gate between glycolysis and the TCA cycle, so they sit on the glucose side of substrate switching. The cofactor role is established; whether supplemental lipoate changes flux in a well-fed person is a separate question.

Riboflavin becomes FAD, the electron acceptor for every acyl-CoA dehydrogenase in the beta-oxidation spiral and for succinate dehydrogenase. Low riboflavin status shows up first in fatty acid oxidation, which is why riboflavin responsiveness is a recognised feature of some oxidation defects. This is settled cofactor biochemistry.

Niacin supplies the nicotinamide ring of NAD and NADP, the electron carriers used by glyceraldehyde-3-phosphate dehydrogenase, the beta-oxidation hydroxyacyl step and the TCA cycle. The NAD to NADH ratio is itself the signal cells read when choosing a fuel. That precursor relationship needs no trial to state.

Nicotinamide riboside is phosphorylated by NRK1 and NRK2 and converted to NAD in two steps, bypassing the rate-limiting NAMPT reaction. Human trials show blood NAD metabolites rise on supplementation, which is a marker and not an energy-metabolism outcome. Pairing it with niacin duplicates a route rather than adding one.

ATP is biologically active as Mg-ATP, so hexokinase, phosphofructokinase and ATP synthase all require magnesium. Magnesium also sits in the active site of enzymes across glycolysis. The requirement is unconditional and is the reason magnesium appears in nearly every metabolic support blend.

Ubiquinone accepts electrons from both NADH dehydrogenase and the fatty-acid-linked electron transfer flavoprotein dehydrogenase, so it is the convergence point of the two fuel routes. Its position in the chain is established biochemistry. Supplemental effects on tissue coenzyme Q content vary with baseline status.

Chromium is proposed to act through chromodulin on insulin receptor kinase activity, which would sit upstream of glucose disposal. Human trials report inconsistent effects on glucose and insulin markers, and markers are not outcomes. It is included in fuel-handling blends for that proposed role rather than a settled one.

A 2026 review positions taurine as an agent that alters adipose tissue metabolism beyond simple weight change, drawing on preclinical and human work. Taurine is also a conjugation partner for bile acids, which links it to fat handling in the gut. The review is a synthesis, so read it as a summary of a direction rather than a single measured effect.

Berberine inhibits mitochondrial complex I in cultured cells, raising the AMP to ATP ratio and activating AMPK, the same sensor that reads cellular fuel status. Human trials report changes in fasting glucose and lipid markers. Those are markers, and berberine has a real interaction profile with medicines cleared through CYP3A4.

Octanoate and other medium-chain fatty acids enter mitochondria without carnitine palmitoyltransferase I, so they are oxidised quickly and readily converted to ketone bodies in the liver. That bypass is why they raise blood ketones within hours. It is a route difference, not evidence of an effect on how the body switches fuels day to day.

EPA and DHA bind PPAR-alpha, the transcription factor that raises expression of fatty acid oxidation enzymes, and they incorporate into mitochondrial and plasma membrane phospholipids. Human trials consistently lower triglycerides, which is a lipid marker. The transcriptional mechanism is well characterised in animal and cell work.

Myo-inositol and D-chiro-inositol form the glycan second messengers released after insulin receptor activation, and the two isomers are interconverted by an epimerase. Human trials report improved insulin sensitivity indices in specific populations. Those indices are calculated markers rather than clinical endpoints.

Cinnamon polyphenols and cinnamaldehyde influence glucose transporter translocation in cell models, and meta-analyses of human trials report modest reductions in fasting glucose with wide heterogeneity. Combining it with other glucose-marker agents stacks the same direction of effect. Anyone using glucose-lowering medicine should have that stacking reviewed by their prescriber.

Gymnemic acids occupy sweet taste receptors and, in intestinal models, reduce glucose uptake at the brush border. Trials are small and older. Because it points the same way as other glucose-marker agents, the combined effect is additive rather than complementary.

Creatine kinase regenerates ATP from phosphocreatine faster than either glycolysis or oxidative phosphorylation can, covering the first seconds of high demand. That buffer sits alongside, not inside, the fuel-switching machinery. Muscle creatine loading with supplementation is one of the most reproducible findings in sports nutrition.

Ribose-5-phosphate is the sugar backbone of ATP, and its synthesis through the non-oxidative pentose phosphate pathway is slow relative to nucleotide loss during heavy demand. Supplemental ribose shortens that resynthesis step in isolated tissue work. Human performance findings are inconsistent.

Without thiamine pyrophosphate, pyruvate cannot be decarboxylated into the TCA cycle and lactate accumulates instead. Transketolase in the pentose phosphate pathway needs the same cofactor. This is one of the clearest cofactor dependencies in fuel handling.

Pantothenate is built into coenzyme A, the carrier for acetyl and acyl groups in beta-oxidation, the TCA cycle and fatty acid synthesis. Both fuel routes converge on acetyl-CoA. The precursor relationship is textbook and needs no citation.

EGCG inhibits catechol-O-methyltransferase, which slows breakdown of noradrenaline and, in short human studies, shifts the respiratory exchange ratio slightly toward fat use during exercise. Effect sizes are small and inconsistent across trials. High-dose concentrated green tea extract carries its own hepatic caution and is not a bulk-dose ingredient.

Caffeine blocks adenosine A1 and A2A receptors, which raises circulating catecholamines and free fatty acids after a dose. The lipolytic response is measurable but habituates with regular intake. It sharpens the availability of one fuel rather than changing the machinery that picks between them.